Status:
UNKNOWN
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
Lead Sponsor:
National Atomic Research Institute, Taiwan
Conditions:
Hepatic Carcinoma
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the...
Detailed Description
This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the...
Eligibility Criteria
Inclusion
- Diagnosed with hepatocellular carcinoma and scheduled to have the PBT.
- 20\~80 years old
- Performance status: ECOG 0-1
- Child-Pugh class A
Exclusion
- Massive or uncontrolled ascites
- Concurrent with other malignancy
- Under pregnancy or breastfeeding
- With distant metastasis
- Allergic to investigational drug(s) or similar drug(s)/ formulation(s);
- Known hypersensitivity to PRIMOVIST
- Acute or chronic severe renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m\^2)
- General PET and MRI exclusion criteria
- Can't follow our follow-up schedule because of any reason
Key Trial Info
Start Date :
December 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06182865
Start Date
December 20 2023
End Date
December 30 2024
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Linkon Chang Gung Memorial Hospital
Taoyuan, Taiwan, 333423